John Bell - Roche Holding Non-Executive Director
RHHBF Stock | USD 268.90 4.15 1.57% |
Director
Prof. John Irving Bell has served as NonExecutive Independent Director of Roche Holding Ltd since 2001. In addition, he acts as Member of the Audit Committee of the Company. In 1975, he gained a Bachelor of Medical Science with Honors from the University of Alberta. In 1976, Prof. Sir Bell gained a Bachelor of Arts with Honors in Physiological Sciences from Magdalen College, Oxford University. In 1979, he gained a Bachelor of Medicine and Bachelor of Surgery from Magdalen College, Oxford University. In 1990, he gained a Doctor of Medicine from Magdalen College, Oxford University. From 1979 until 1982, he carried out postgraduate clinical training in Oxford and London. From 1982 until 1987, Prof. Sir Bell was Clinical Fellow in the Department of Medicine at Stanford University and also Postdoctoral Fellow in the Department of Medical Microbiology at Stanford University. From 1987 until 1989, he was Wellcome Senior Clinical Fellow and Honorary Consultant Physician in the Nuffield Departments of Clinical Medicine and Surgery at John Radcliffe Hospital, Oxford. From 1989 until 1992, he was University Lecturer at the Nuffield Department of Clinical Medicine at Oxford University. From 1992 until 2002, he was Nuffield Professor of Clinical Medicine at Oxford University. Since 2002, Prof. Bell was Regius Professor of Medicine at Oxford University. He has also been Honorary Consultant Physician at Oxford Radcliffe NHS Trust since 1987 Nuffield Professor of Clinical Medicine Chairman at the Department of Medicine, Oxford University School of Medicine, since 1992 Founder of the Wellcome Trust Centre for Human Genetics since 1993 Chairman of the Partnership Board at the Oxford Centre for Diabetes, Endocrinology and Metabolism since 1999 Chairman of the Trials and Epidemiology Building, Oxford since 1999 and President of the Academy of Medical Sciences since 2006. He was knighted in the 2008 Honors list for Services to Medicine. since 2001.
Age | 65 |
Tenure | 23 years |
Professional Marks | Ph.D |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Christine Seidman | Merck Company | 68 | |
Nazneen Rahman | AstraZeneca PLC | N/A | |
Carolyn Bertozzi | Eli Lilly And | 53 | |
Deborah DiSanzo | AstraZeneca PLC | 58 | |
Susan Lindquist | Johnson Johnson | 65 | |
Peter Voser | Roche Holding | 59 | |
William Kaelin | Eli Lilly And | 63 | |
Ralph Alvarez | Eli Lilly And | 63 | |
Scott Davis | Johnson Johnson | 66 | |
Paul Rothman | Merck Company | 63 | |
Richard Lifton | Roche Holding AG | 65 | |
Eugene Washington | Johnson Johnson | 67 | |
Craig Thompson | Merck Company | 64 | |
William Perez | Johnson Johnson | 71 | |
Cornelia Bargmann | AstraZeneca PLC ADR | N/A | |
Ton Buechner | Novartis AG ADR | 55 | |
Mark McClellan | Johnson Johnson | 57 | |
Pierre Landolt | Novartis AG ADR | 70 | |
Claudia Dyckerhoff | Roche Holding AG | 51 | |
Simon Moroney | Novartis AG ADR | 62 | |
Enrico Vanni | Novartis AG | 67 |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
Bruno Eschli, Head Relations | ||
Silvia Ayyoubi, Head of Group HR | ||
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
Thomas Schinecker, Chief Diagnostics | ||
Beatrice Mauro, Non-Executive Director | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
Gottlieb Keller, General Counsel and Corporate Secretary | ||
Urs Jaisli, Chief Compliance Officer | ||
Daniel ODay, COO of Pharmaceuticals division | ||
Claudia Bockstiegel, G Counsel | ||
DeAnne Julius, Non-Executive Director | ||
Johannes MD, Head Devel | ||
Karl Mahler, Head of Investor Relations | ||
Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
Claudia Dyckerhoff, Non-Executive Director | ||
Fritz Gerber, Honorary Chairman of the Board | ||
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
Julie Brown, Non-Executive Director | ||
Richard Lifton, Non-Executive Director | ||
Paul Bulcke, Non-Executive Director | ||
Christoph Franz, Non-Executive Director | ||
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
Pascale Schmidt, Chief Officer | ||
Pius Baschera, Non-Executive Director | ||
Peter Voser, Non-Executive Director | ||
Bernard Poussot, Non-Executive Director | ||
John Bell, Non-Executive Director | ||
Andreas Oeri, Non-Executive Director | ||
Alan Hippe, CFO and IT Officer | ||
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
F Hoffmann, IR Contact Officer | ||
Severin Schwan, CEO and Director | ||
Anita Hauser, Non-Executive Director | ||
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 287.91 B | |||
Shares Outstanding | 106.69 M | |||
Shares Owned By Insiders | 75.31 % | |||
Shares Owned By Institutions | 8.56 % | |||
Price To Earning | 21.63 X | |||
Price To Book | 11.61 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding AG information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |